Moonlight Ai GmbH

Based in Switzerland, Moonlight AI GmbH provides an innovative diagnostics platform leveraging artificial intelligence to enhance disease detection through genomic biomarker analysis in hematology and cytology. Moonlight AI GmbH, founded in 2022, It is headquartered in Switzerland. Founded by Christian Ruiz9(CEO), Nicole H. Romano(CTO), and Stefan Habringer(CMO).

specializes in advanced diagnostics using AI technology to analyze imaging data for complex disease diagnosis. The latest funding round, a Seed round amounting to USD 3. 3 mn, was closed in May 2026, co-led by Lotus One Investment, VP Venture Partners, and Medin Fund Management Company, with participation from investor N & V Capital and QAI Ventures. Moonlight AI's primary offering is its advanced diagnostics platform that utilizes artificial intelligence to analyze routine imaging from hematology and cytology smears.

The platform focuses on detecting genomic biomarkers and diagnosing complex diseases by interpreting the morphology of tumor cells, serving as an indicator of their genomic and molecular profiles. The software integrates seamlessly with existing imaging hardware in diagnostic laboratories, enhancing workflows in hematology and cytopathology. By enabling rapid access to genomic insights, Moonlight AI complements conventional molecular testing methods, addressing the significant gap in guideline-recommended testing for cancer patients. The platform primarily targets diagnostic laboratories in the United States and Europe, where scalable and cost-effective molecular testing solutions are critical.

Moonlight AI generates revenue through the provision of its AI diagnostics software to diagnostic laboratories, operating on a B2B model. These transactions are structured as partnerships with labs that subscribe to the software to enhance their diagnostic capabilities. The firm’s business model includes tiered pricing plans based on the volume of tests conducted or specific functionalities utilized within the platform. Diagnostic labs may pay a subscription fee that varies with the number of slides analyzed or the additional features required, promoting wider adoption of their AI solutions in the healthcare diagnostics sector.

In May 2026, Moonlight Ai GmbH raised USD 3. 3 mn in Seed funding, which will be utilized to expand its dataset, grow its team, and advance its programs toward commercialization and regulatory approval. The company plans to launch new features that enhance their AI platform, aiming for release by mid-2027. Additionally, Moonlight AI intends to expand its market presence in North America and Europe, targeting diagnostic labs that require advanced molecular testing capabilities by the end of 2027.